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Abstract
Background: Tumor recurrence and metastasis are the most common reason for treatment failure. Metastasis-associate
in colon cancer-1 (MACC1) has been identified as a metastatic and prognostic biomarker for colorectal cancer and other
solid tumors. Aldehyde dehydrogenase 1 (ALDH1), a marker of cancer stem cells, is also associated with metastasis and
poor prognosis in many tumors. However, the prognostic value of either MACC1 or ALDH1 in non-small cell lung cancer
(NSCLC) is unclear. In this study, we explored the relationship between MACC1 and ALDH1 expression, as well as their
respective associations with clinicopathological features, to determine if either could be useful for improvement of
survival prognosis in NSCLC.
Methods: The expression levels of both MACC1 and ALDH1 in 240 whole tissue sections of NSCLC were examined by
immunohistochemistry. Clinical data were also collected.
Results: MACC1 and ALDH1 were significantly overexpressed in NSCLC tissues when compared to levels in normal lung
tissues. Investigation of associations between MACC1 or ALDH1 protein levels with clinicopathological parameters of
NSCLC revealed correlations between the expression of each with tumor grade, lymph node metastasis, and tumor
node metastasis. The overall survival of patients with MACC1- or ALDH1-positive NSCLC tumors was significantly lower
than that of those who were negative. Importantly, multivariate analysis suggested that positive expression of either
MACC1 or ALDH1, as well as TNM stage, could be independent prognostic factors for overall survival in patients with
NSCLC.
Conclusions: MACC1 and ALDH1 may represent promising metastatic and prognostic biomarkers, as well as potential
therapeutic targets, for NSCLC.
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Background
New lung cancer cases were estimated at 1.8 million and
accounted for nearly 13 % of all new cancer cases in
2012, making it the most commonly diagnosed cancer
worldwide [1]. It was also the most frequent cause of
cancer-related death. Non-small cell lung cancer
(NSCLC) accounts for approximately 85 % of all
diagnosed lung cancers [2]; it has an overall 5-year sur-
vival rate of less than 20 % [2]. In China, the majority of
patients diagnosed with NSCLC have advanced stage
disease and are unsuitable for curative surgery.
The leading causes of cancer treatment failure are
recurrence and metastasis. One gene that contributes to
these processes is metastasis-associated in colon cancer-
1 (MACC1). MACC1 is a critical regulator of the HGF/
MET signaling pathway. It was first identified in colon
cancer where it bound to the promoter of the MET gene
to control its transcriptional activity [3, 4]. It has been
shown to promote tumor cell migration and invasion in
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vitro and to induce tumor growth and metastasis in vivo
[3, 5, 6]. MACC1 is considered an independent factor
for prognosis and metastasis in colorectal cancer [3, 7].
Accumulating studies suggest that it could also be a
prognostic and metastatic factor for other cancers, such
as breast cancer [8], gastric carcinoma [9], hepatocellular
carcinoma [10], renal pelvis carcinoma [11], malignant
glioma [12], cervical carcinoma [13], and lung cancer
[5].
Cancer stem cells (CSCs), also known as tumor-
initiating cells, are a small population of cells within a
tumor that have the capacity to self-renew and give rise
to differentiated cell populations [14]. They are relatively
resistant to chemotherapy and radiotherapy. These prop-
erties allow CSCs to repopulate tumors following treat-
ment and lead to recurrence or metastasis [15–17].
Aldehyde dehydrogenases (ALDH) represent a family of
enzymes located in the nucleus, cytoplasm, and mito-
chondria. ALDHs not only detoxify intracellular alde-
hydes or some cytotoxic drugs, but are also a key feature
of CSCs [17–19]. ALDH1, which mainly promotes the
conversion of retinaldehyde to retinoic acid, plays an
important role in cell proliferation and differentiation in
vitamin A metabolism [20–22]. Its overexpression can
increase the risk of alcohol-related cancers [23]. More-
over, ALDH1 has been associated with metastasis and
poor prognosis in many human cancers, such as breast
cancer [24], ovarian cancer [17], lung cancer [18], and
pancreatic cancer [25].
The involvement of MACC1 and ALDH1 in the recur-
rence and metastasis of NSCLC suggest that they could be
valuable biomarkers for measuring disease progression
and developing more accurate therapeutic strategies. To
our knowledge, an association between MACC1 and
ALDH1 in NSCLC has not yet been reported. In this
study, we investigated the relationship between MACC1
and ALDH1 expression in patient tumor sections as well
as compared their expression with the clinicopathology
and prognosis of NSCLC.
Methods
Biopsy specimens
NSCLC tissues and adjacent noncancerous lung tissues
were collected at the Department of Pathology of the
First Affiliated Hospital of Bengbu Medical College, from
January 2008 to December 2009. Patients who had
received preoperative chemotherapy or radiotherapy, or
other anti-cancer therapies, were excluded. All tissue
samples were obtained with patient consent and the study
was approved by the ethical committee of the Bengbu
Medical College. The study group consisted of 240
patients, 160 males and 80 females, aged from 28–81 years;
the average age was 58.3 ± 10.7 years. Tumor stage was
assessed according to the 7th edition of the American
Joint Committee on Cancer. Of the 240 NSCLC tissue
samples, 33 were grade I, 157 were grade II, and 50 were
grade III. As for histological type, 160 were characterized
as squamous cell carcinoma while the remaining 80 were
adenocarcinoma.
Immunohistochemistry
Immunohistochemistry was performed according to the
Elivision Plus detection kit instructions (Lab Vision,
USA). Briefly, NSCLC- and corresponding normal lung
tissues were fixed in 10 % buffered formalin and embed-
ded in paraffin. Continuous 4 μm thick tissue sections
were cut. All sections were deparaffinized and dehy-
drated with xylene and graded ethanol, then washed for
10 min in PBS (pH 7.2). Endogenous peroxidase activity
was quenched by incubation of sections in methanol
containing 3 % hydrogen peroxide for 10 min at RT, they
were then placed in citrate buffer (pH 6.0) for antigen
repair. After several washes in PBS, the sections were
blocked with goat serum for 20 min at RT then incu-
bated with mouse monoclonal antibody against human
ALDH1 (Abcam, Cambridge, MA, USA) or rabbit
polyclonal antibody against human MACC1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 h at 37 °C.
All slides were counterstained with hematoxylin, dehy-
drated, air-dried, and mounted. Negative controls were
prepared by omitting primary antibodies from the stain-
ing procedure. MACC1 and ALDH1 positive staining
was mainly located in the cytoplasm of cancer cells.
Evaluation of staining
Staining results were interpreted by two independent
pathologists who were blind to clinical data and judged by
semi-quantitative points. To overcome the intratumoral
heterogeneity of antigen expression, ten visual fields from
different areas of each NSCLC tumor were examined. If
there was a disagreement, the observers would reexamine
the section and reach a consensus [15, 26–28]. Staining
was scored according to intensity and extent. The staining
intensity score was graded as: 0, none; 1, weak; 2, moder-
ate; and 3, strong. The extent of positive staining was
graded as: 1, <10 %; 2, 11–50 %; 3, 51–75 %; and 4, >75 %.
The intensity and extent scores were then multiplied to
yield a final score that ranged from 0–12. Expression was
considered positive when the score was ≥3. For tissues
that were positive for both MACC1 and ALDH1, an
average of the final score of each was taken.
Statistical analysis
Relationships between either MACC1- or ALDH1 pro-
tein expression and clinicopathological variables were
compared using Fisher’s exact test or Chi-square test.
The association between MACC1 and ALDH1 protein
expression was compared using Spearman’s coefficient
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test. The effects of MACC1 and ALDH1 expression on
survival were determined by univariate and multivariate
analyses. Independent prognostic factors were deter-
mined using the Cox regression model for multivariate
analysis. The Kaplan-Meier method with log-rank test
for univariate overall survival analysis was used to assess
the relationship between the positive expression of either
MACC1 or ALDH1 and clinicopathological factors using
SPSS 19.0 software for Windows (Chicago, IL). A value
of P < 0.05 was defined as statistically significant.
Results
Expression of MACC1 and ALDH1 in NSCLC, and their
relationship to clinicopathology
To evaluate the contributions of MACC1 and ALDH1
to NSCLC, their expression levels were assessed in both
NSCLC and normal lung tissue sections using immuno-
histochemistry. These data were then compared to clini-
copathological parameters. The positive rate of MACC1
protein expression was 64.2 % (154/240) in NSCLC
tissues and 9.6 % (23/240) in normal lung tissues
(Fig. 1a–b) and this difference was found to be statisti-
cally significant (P < 0.001). There were also significant
differences between the positive expression of MACC1
and tumor grade (P = 0.015), lymph node metastasis
(LNM) (P < 0.001), and tumor node metastasis (TNM)
(P = 0.001). In contrast, there were no correlations detected
between MACC1 expression and patient age (P = 0.622),
gender (P = 0.341), tumor diameter (P = 0.490), loca-
tion (P = 0.575), or histological type (P = 0.505).
Similar to MACC1, the expression of ALDH1 was
significantly greater in NSCLC- than in control tissues,
with positive rates of 55.8 % (134/240) and 12.5 % (30/
240), respectively (P < 0.001) (Fig. 1c–d). There were also
positive correlations between high expression of ALDH1 in
NSCLC and tumor grade, LNM, and TNM (all P < 0.001).
Furthermore, patients with squamous cell carcinoma had a
higher positive rate of ALDH1 expression than did those
with adenocarcinoma (P = 0.035). There were no associa-
tions detected between ALDH1 expression and patient age
(P = 0.918), gender (P = 0.854), tumor diameter (P = 0.596),
or location (P = 0.677) (Table 1).
Univariate and multivariate analysis
Follow-up data showed that overall survival was signifi-
cantly reduced in NSCLC patients with positive expres-
sion of MACC1 (42.1 months) compared to those who
were MACC1-negative (54.2 months) (log-rank = 20.316,
P < 0.001) (Fig. 2a). Similarly, the survival of ALDH1-
positive patients (42.0 months) was significantly shorter
than those whose tumors were negative (52.1 months)
(log-rank = 17.065, P < 0.001) (Fig. 2b). Overall survival
was also influenced by tumor grade, whereby NSCLC
patients with low grade tumors survived significantly
longer than those with tumors rated either moderate
(log-rank = 12.826, P < 0.001) or poor (log-rank = 4.909,
P = 0.027). There was no significant difference between
Fig. 1 Representative results of MACC1 and ALDH1 in non-small cell lung cancer and control group. a: Control bronchiolar epithelial cells
expressed MACC1 in the cytoplasm. b: MACC1 predominantly localized in the cytoplasm in moderately grade of squamous cell carcinoma
(MACC1 × 400). c: Control bronchiolar epithelial cells expressed ALDH1 in the cytoplasm. d: ALDH1 predominantly localized in the cytoplasm in
moderately grade of squamous cell carcinoma (ALDH1 × 400)
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the survival of patients with moderate or poor grade
NSCLCs (log-rank = 1.524, P= 0.217) (Fig. 3a). Positive LNM
was also linked with significantly reduced survival when
compared with the no LNM group (log-rank = 11.148, P=
0.001) (Fig. 3b). The survival of stage I patients was signifi-
cantly longer than that of those with either stage II (log-rank
= 6.688, P= 0.010) or stage III NSCLC (log-rank = 16.359, P
< 0.001). The survival of stage II patients was also sig-
nificantly longer than that of those with stage III
NSCLC (log-rank = 4.219, P = 0.040) (Fig. 3c).
Multivariate analysis showed that positive expression of
either MACC1 or ALDH1, as well as TNM stage, were
independent prognostic factors for NSCLC (Table 2).
Association between the expression of MACC1 and
ALDH1 in NSCLC
Spearman association coefficient analysis revealed a
positive association between the expression of MACC1
and that of ALDH1 (r = 0.368, P < 0.001).
Table 1 Correlation between the expression of MACC1 and ALDH1 and clinicopathololgical characteristics in NSCLC
Variable MACC1 P value ALDH1 P value
negative positive negative positive
Tissue <0.001 <0.001
Normal 217 23 210 30
NSCLC 86 154 106 134
Gender 0.341 0.854
Male 54 106 70 90
Female 32 48 36 44
Age (years) 0.622 0.918
< 60 38 63 45 56
≥ 60 48 91 61 78
Gross type 0.575 0.677
Central 60 102 70 92
Peripheral 26 52 36 42
Histological type 0.505 0.035
Squamous cell carcinoma 55 105 63 97
Adenocarcinoma 31 49 43 37
Diameter of tumor 0.490 0.596
< 3.0 cm 17 25 17 25
≥ 3.0 cm 69 129 89 109
Grade of tumor 0.015 <0.001
Well 19 14 26 7
Moderately 53 104 70 87
Poorly 14 36 10 40
Lymph node metastasis <0.001 <0.001
No 56 60 84 32
Yes 30 94 22 102
TNM stage 0.001 <0.001
I 18 14 25 7
II 38 50 60 28
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Discussion
NSCLC is a highly heterogeneous disease. This heterogen-
eity may affect the reproducibility of biomarker assess-
ment [29, 30]. Thorough investigation of the prognostic
value of candidate biomarkers is thus required to ensure
validity. In this study, we analyzed MACC1 expression in
NSCLC and matched normal tissues from 240 patients
and compared it to clinicopathological parameters. We
found that MACC1 expression was significantly greater in
NSCLC tissues than in normal lung tissues. Moreover, it
was positively associated with tumor grade, LNM, and
TNM. Our findings are consistent with previous studies in
NSCLC [31–35] suggesting that MACC1 could be useful
as a clinical biomarker of NSCLC.
ALDH1, an intracellular enzyme related to retinoic
acid, is widely regarded as a CSC marker in many
cancers [18, 21, 25, 36–38]. In NSCLC, ALDH1 has been
associated with carcinogenesis [39] and shown to predict
Fig. 2 Kaplan-Meier survival analysis by MACC1 and ALDH1 status (n = 240). The y-axis represents the percentage of patient; the x-axis, their survival in
months. The green line represents patients with positive expression of MACC1 (a) or ALDH1 (b) with a trend of worse survival time than the blue line
representing the negative MACC1 group or ALDH1 group (P < 0.001). Mean survival time was 42.1 months for the positive expression of MACC1 group
and 54.2 months for the negative MACC1 group. Mean survival time was 42.0 months for the positive expression of ALDH1 group and 52.1 months for
the negative ALDH1 group
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a poor response to both chemotherapy and radiotherapy
[28]. In our study, we found that ALDH1 expression was
significantly related to tumor grade, LNM, and TNM.
Furthermore, Kaplan-Meier survival analysis demonstrated
that NSCLC patients with positive ALDH1 expression had
significantly reduced survival compared with that of those
negative for ALDH1. These findings suggest that ALDH1
plays an important role in the tumorigenesis, development,
progression, metastasis, and prognosis of NSCLC. Several
other immunohistochemical studies that examined the
metastatic and prognostic significance of ALDH1 in
NSCLC patients obtained similar results [18, 40, 41]. In
addition, because squamous cell carcinomas tend to
develop more rapidly than andenocarcinomas, could this
suggest that ALDH1 is a good biomarker for more aggres-
sive NSCLC. This is also consistent with a previous study
[42]. Thus, our findings support the notion that ALDH1
Fig. 3 Kaplan-Meier survival analysis by grade, lymph node metastasis, and TNM stages status (n = 240). The y-axis represents the percentage of
patient; the x-axis, their survival in months. a The green line represents patients with moderate grade of NSCLC with a trend of worse survival time
than the blue line representing the well grade group (P < 0.001). Mean survival time was 44.1 months for the moderate grade of NSCLC group
and 58.2 months for the well grade of NSCLC group. The brown line represents patients with poor grade of NSCLC with a trend of worse survival
time than the blue line representing the well grade group (P = 0.027). b The green line represents patients with LNM of NSCLC with a trend of
worse survival time than the blue line representing the no LNM group (P = 0.001). c The green line represents patients with stageII of NSCLC with
a trend of worse survival time than the blue line representing the stageIgroup (P = 0.010). The brown line represents patients with stage III of
NSCLC with a trend of worse survival time than the blue line representing the stage I group (P < 0.001). The brown line represents patients with
stage III of NSCLC with a trend of worse survival time than the blue line representing the stage II group (P = 0.040)
Table 2 Multivariate survival analysis of 240 patients with NSCLC
Covariate B SE P value Exp (B) 95 % CI
MACC1 0.505 0.166 0.002 1.657 1.198–2.292
ALDH1 0.468 0.181 0.010 1.597 1.120–2.279
TNM stage 0.887 0.259 0.001 2.428 1.461–4.034
Zhou et al. BMC Cancer  (2016) 16:876 Page 6 of 8
would be a reliable biomarker of NSCLC, in particularly for
predicting metastasis and disease progression.
Recurrence and metastasis are the most common
causes of deaths in NSCLC. TNM staging is well-known
as the guide for designing therapeutic strategies for pa-
tients with NSCLC, however, it provides limited infor-
mation on the biological behavior of the disease. It is
thus critical to find novel and effective prognostic strat-
egies to predict recurrence and metastasis in NSCLC
patients. In this study, multivariate Cox model analysis
suggested that the positive expression of either MACC1
or ALDH1, as well as TNM stage, are independent
prognostic factors for patients with NSCLC.
Abnormal ALDH1 expression may be involved in the
initiation and recurrence of NSCLC through its involve-
ment in CSCs. Among other things, self-renewal, prolif-
eration, and an aptitude for multiple differentiation
allow CSCs to induce angiogenesis and lymphangiogen-
esis to thereby access adequate nutrition and oxygen for
rapid tumor growth. Indeed, the niche where CSCs
reside mainly consists of vascular and lymphatic vessels.
Meanwhile, MACC1 contributes to tumorigenesis
through the promotion of cancer cell proliferation and
invasion through activation of the HGF/ Met signaling
pathway [3, 4]. It is also involved in angiogenesis and
lymphangiogenesis to promote tumor invasion and me-
tastasis [43, 44]. In turn, these microvessels and micro-
lymphantic vessels sustain CSCs that further promote
tumor invasion and metastasis, thus creating a positive
cycle of tumor advancement.
Conclusions
Our findings suggest that aberrant expression of MACC1
and ALDH1 may play important roles in the development
of NSCLC. The combined detection of MACC1 and
ALDH1 may thus be valuable as markers for metastasis
and thereby prognosis for patients with NSCLC.
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